Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ergoferon (Materia Medica Holding)
- Development stage
- Phase 3
- Lead developer
- Materia Medica Holding
- Modality
- Antibody-Based Therapeutics
- Administration
- Oral
01
Overview
MMH-407, commercially known as **Ergoferon**, is a multi-component antiviral and anti-inflammatory drug developed by the Russian company **Materia Medica Holding**. It is composed of "release-active" (highly diluted) affinity-purified antibodies directed against three specific targets: human interferon-gamma (IFN-γ), the CD4 receptor, and histamine. The drug is designed to treat and prevent influenza and other acute respiratory viral infections (ARVI) by modulating the functional activity of these targets, thereby enhancing the body's antiviral immune response and reducing allergic-like inflammatory reactions. While it is marketed and clinically studied in Russia and several CIS countries, its pharmacological mechanism—based on dilutions that exceed the Avogadro limit—remains a subject of scientific debate within the international community.
- Brand names
- Ergoferon
- Other names
- ЭргоферонRelease-active antibodies to IFN-gamma, CD4, and histamine
02
Targets
CD4 (T lymphocyte surface antigen)IFNG (Interferon gamma)
Beyond the preview
Go deeper on Ergoferon (Materia Medica Holding).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ergoferon (Materia Medica Holding).